Recent advances in gene therapy for bone tissue engineering.

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Gene Therapy

Background:

• Autografting for bone fractures carries risks like surgical complications and disease transmission.
• Bone morphogenetic proteins (BMPs) are effective osteogenic factors but face challenges with short half-life and high recombinant protein costs.
• Current BMP delivery methods require improvement for efficient bone healing applications.

Purpose of the Study:

• To review recent advancements in gene delivery systems for bone repair and regeneration.
• To explore engineered viral, non-viral, and RNA-mediated strategies for therapeutic gene delivery.
• To discuss the role of CRISPR/Cas9 genome engineering in bone tissue regeneration.

Main Methods:

• Review of current literature on gene delivery systems for bone regeneration.
• Analysis of engineered viral vectors (e.g., AAV, lentivirus) for therapeutic gene delivery.
• Evaluation of non-viral methods (e.g., nanoparticles, electroporation) and RNA-mediated delivery.
• Exploration of clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) applications in bone regeneration.

Main Results:

• Engineered gene delivery systems show potential for localized and sustained production of osteogenic factors.
• Viral and non-viral gene delivery methods offer alternative strategies to overcome BMP limitations.
• RNA-mediated delivery presents a transient and potentially safer gene modulation approach.
• CRISPR/Cas9 technology is emerging as a powerful tool for precise genome engineering in bone regeneration.

Conclusions:

• Gene delivery systems represent a significant advancement over traditional autografting for bone repair.
• Engineered cells utilizing viral, non-viral, and RNA-mediated gene delivery can enhance bone regeneration.
• CRISPR/Cas9 technology holds future promise for targeted bone tissue regeneration strategies.